ArticleJournal of cosmetic dermatology2025
The Efficacy and Safety of Combining Cross-Linked Hyaluronic Acid Filler VYC-12L and Energy-Based Devices for Facial Skin Quality Improvement in Asians.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The Efficacy and Safety of Combining Cross-Linked Hyaluronic Acid Filler VYC-12L and Energy-Based Devices for Facial Skin Quality Improvement in Asians.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, treatments using energy-based devices (EBDs) aimed at skin quality improvement have become widely adopted. However, it has been pointed out that treatments using EBDs alone show limited durability of effects and variability in patient-perceived improvements. Therefore, we evaluated skin quality improvement resulting from a combination therapy involving cross-linked hyaluronic acid (CL-HA) filler and EBD treatments tailored to patients' chief concerns.
objectiveTo assess the efficacy and safety of combined CL-HA filler and EBD therapies in treating facial skin quality improvement among Asian subjects.
methodsIn this prospective, evaluator-blinded study, 18 participants aged 32-59 years with decreased skin elasticity, fine wrinkles, uneven texture, pore enlargement, pigmentation, and sagging were enrolled. CL-HA filler (VYC-12L) was injected intradermally into the entire face. One month later, according to each patient's primary concerns and symptoms, EBD treatment (either high intensity, high frequency parallel ultrasound beam [PUB], picosecond alexandrite laser [PSAL], and sequential monopolar bipolar pulsed radiofrequency [SMBPRF]) was administered to the entire face. Evaluations were conducted at three time points: baseline (T0), 4 weeks post-CL-HA injection (T1), and 8 weeks post-EBD treatment (T2). Subjective assessment was performed using the FACE-Q | Aesthetics-Satisfaction with Skin scale. Objective assessment was independently conducted by a dermatologist utilizing three-dimensional image analysis and skin diagnostic imaging with the Global Aesthetic Improvement Scale (GAIS).
resultsAll participants completed the study. Pairwise comparisons of the FACE-Q skin satisfaction scores demonstrated statistically significant improvements at all time points: from T0 to T1 (p < 0.05), from T0 to T2 (p < 0.001), and from T1 to T2 (p < 0.001). Objective assessment with the GAIS showed improvement in all cases: very much improved (2 cases), much improved (9 cases), improved (7 cases), no change (0 cases), and worsened (0 cases). Regarding safety, no severe adverse events were reported, and only minor transient post-treatment reactions were observed.
conclusionsThe combination of CL-HA filler and EBD represents a safe and effective therapeutic approach for enhancing facial skin quality in Asian subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.